GSK-1292263

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H28N4O4S
Molecular Weight	456.558
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C1=NOC(=N1)N2CCC(COC3=CC=C(N=C3)C4=CC=C(C=C4)S(C)(=O)=O)CC2

InChI

InChIKey=AYJRTVVIBJSSKN-UHFFFAOYSA-N

InChI=1S/C23H28N4O4S/c1-16(2)22-25-23(31-26-22)27-12-10-17(11-13-27)15-30-19-6-9-21(24-14-19)18-4-7-20(8-5-18)32(3,28)29/h4-9,14,16-17H,10-13,15H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C23H28N4O4S
Molecular Weight	456.558
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24699248
Curator's Comment: Description was created based on several sources, including http://www.eurodiagnostico.com/media/pdf/GSK1292263.pdf http://adisinsight.springer.com/drugs/800029184

GSK1292263 (GSK263) (5-[({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}methyl)oxy]-2-[4-(methylsulfonyl)phenyl]pyridine) is a potent and selective agonist at the rodent and human GPR119 receptors that was discovered at GlaxoSmithKline. It has a pEC50 = 6.8 for human, rat and mouse GPR119 receptors expressed in an in vitro reporter assay, and a pEC50 = 8.5 for the stimulation of GLP-1 secretion from GLUTag cells. Like other GPR119 agonists, GSK1292263 increases glucose-sensitive insulin secretion, improves glucose tolerance and enhances the secretion of gut hormones in normal rats. GSK1292263 has finished Phase II clinical trial for Diabetes Mellitus, Type 2.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Glucose-dependent insulinotropic receptor 13 Target ID: CHEMBL5652 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24699248	Agonist 2678	6.8 null [pEC50]
ATP-binding cassette sub-family G member 2 16 Target ID: CHEMBL5393 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23256625	Inhibitor 8297
Solute carrier organic anion transporter family member 1B1 32 Target ID: CHEMBL1697668 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23256625	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dyslipidemia 30 Sources: https://clinicaltrials.gov/ct2/show/NCT01218204	Primary		Phase II 1132	Unknown Approved Use Unknown
Type 2 diabetes mellitus 259 Sources: https://clinicaltrials.gov/ct2/show/NCT01119846	Primary		Phase II 1132	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
870 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23256625	300 mg 2 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: ROSUVASTATIN	ROSUVASTATIN	GSK-1292263 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
13956 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23256625	300 mg 2 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: ROSUVASTATIN	ROSUVASTATIN	GSK-1292263 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23256625	300 mg 2 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: ROSUVASTATIN	ROSUVASTATIN	GSK-1292263 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY115417	https://www.001chemical.com/chem/search?q=DY115417
1PlusChem LLC	1P008TXB	https://www.1pchem.com/search?query=1P008TXB
A2B Chem	AE11231	http://a2bchem.com/prod/AE11231
AA Blocks	AA008TDV	http://aablocks.com/goods/Goods/detail?id=AA008TDV
AK Scientific	0781AA	https://aksci.com/item_detail.php?cat=0781AA
Angene	AGN-PC-0OSAHN	http://www.angenechemical.com/productshow/AGN-PC-0OSAHN.html
ApexBio Technology	A8439	https://www.apexbt.com/catalogsearch/result/?q=A8439
AstaTech	W11669	http://astatechinc.com/CPSResult.php?CRNO=W11669
BOC Sciences	1032823-75-8	http://www.bocsci.com/description.asp?cas=1032823-75-8
Capot Chemical	22429	https://www.capotchem.com/search.do?q=22429
ChemShuttle	141516	https://www.chemshuttle.com/catalogsearch/result/?q=141516
Debye Scientific	DA-38881	https://www.debyesci.com/index.php?id=product&ext[cno]=DA-38881
Excenen	EX-A042	http://www.excenen.com/searchresultlist.php?id=EX-A042
Hairui	HR144102	http://www.hairuichem.com/en/product/search.do?q=HR144102
KeyOrganics	AS-56171	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-56171
Matrix Scientific	100448	http://www.matrixscientific.com/100448.html
MedChem Express	HY-12066	https://www.medchemexpress.com/search.html?q=HY-12066&ft=&fa=&fp=
MolPort	MolPort-016-633-286	https://www.molport.com/shop/molecule-link/MolPort-016-633-286
Molcore	MC115417	http://www.molcore.com/CatMC115417.html
Molnova	M10159	https://www.molnova.com/en/serch-list.html?keywords=M10159
Selleck Chemicals	S2149	http://www.selleckchem.com/search.html?searchDTO.searchParam=S2149
ShangHai Biochempartner	BCP000330	http://www.biochempartner.com/search_BCP000330
ShangHai Biochempartner	BCP02375	http://www.biochempartner.com/search_BCP02375
TargetMol	T2701	https://www.targetmol.com/search?keyword=T2701
WuXi AppTec	WXC02799	https://www.labnetwork.com/frontend-app/p/#!/supplier/wuxi/product/WXC02799
eMolecules	32278192	https://orderbb.emolecules.com/search/#?query=32278192
eMolecules	43611694	https://orderbb.emolecules.com/search/#?query=43611694
eNovation Chemicals	D210795	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D210795&searchbtn.x=0&searchbtn.y=0
eNovation Chemicals	D320263	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D320263&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-3511580786	https://mcule.com/MCULE-3511580786/

PubMed

Title	Date	PubMed
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.	2014	24699248

Patents

Sample Use Guides

In Vivo Use Guide

GSK1292263 was administered as single (25-800 mg) or multiple doses (100-600 mg/day for 14 days)

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:15:24 GMT 2023` Edited by `admin` on `Fri Dec 15 18:15:24 GMT 2023`
Record UNII	R1J57STA6O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GSK-1292263

Code

English

5-(((1-(3-(1-METHYLETHYL)-1,2,4-OXADIAZOL-5-YL)-4-PIPERIDINYL)METHYL)OXY)-2-(4-(METHYLSULFONYL)PHENYL)PYRIDINE

Systematic Name

English

GSK1292263

Code

English

GSK 1292263 [WHO-DD]

Common Name

English

GSK-1292263A

Code

English

PYRIDINE, 5-((1-(3-(1-METHYLETHYL)-1,2,4-OXADIAZOL-5-YL)-4-PIPERIDINYL)METHOXY)-2-(4-(METHYLSULFONYL)PHENYL)-

Systematic Name

English

GSK-263A

Code

English

Code System Code Type Description

CAS

1032823-75-8